Fiona Lawrence
General Counsel at ARECOR THERAPEUTICS PLC
Net worth: 123 061 $ as of 2024-04-29
Fiona Lawrence active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ARECOR THERAPEUTICS PLC | General Counsel | - | - |
Career history of Fiona Lawrence
Former positions of Fiona Lawrence
| Companies | Position | Start | End |
|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Corporate Officer/Principal | - | - |
| BioMarin Nederland BV | Corporate Officer/Principal | - | - |
| Prosensa Therapeutics BV | Corporate Officer/Principal | - | - |
Duchenne UK
 Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Chief Tech/Sci/R&D Officer | - | - |
Training of Fiona Lawrence
| University of Bath | Undergraduate Degree |
| University of Surrey | Graduate Degree |
Statistics
International
| United Kingdom | 6 |
| Netherlands | 3 |
Operational
| Corporate Officer/Principal | 3 |
| General Counsel | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 3 |
| Miscellaneous | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ARECOR THERAPEUTICS PLC | Health Technology |
| Private companies | 4 |
|---|---|
| Prosensa Therapeutics BV | Health Technology |
| BioMarin Nederland BV | |
Duchenne UK
Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Miscellaneous |
| Cambridge University Hospitals NHS Foundation Trust | Health Services |
- Stock Market
- Insiders
- Fiona Lawrence
- Experience
